AC Immune Ltd
$ 2.88
1.05%
04 Dec - close price
- Market Cap 289,728,000 USD
- Current Price $ 2.88
- High / Low $ 2.90 / 2.72
- Stock P/E N/A
- Book Value 0.62
- EPS -0.90
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.75 %
- 52 Week High 4.00
- 52 Week Low 1.43
About
AC Immune Ltd (Ticker: ACIU) is an innovative clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in transformative therapies and diagnostics for neurodegenerative conditions associated with protein misfolding, particularly Alzheimer's disease. Utilizing its proprietary technology platforms, the company is dedicated to advancing a diverse pipeline of drug candidates designed to modify disease progression and improve patient outcomes. With a strategic focus on addressing critical unmet needs in neurology, AC Immune presents a compelling investment opportunity for institutional investors seeking to capitalize on breakthroughs in the biopharmaceutical landscape.
Analyst Target Price
$9.74
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-05 | 2025-05-12 | 2025-03-12 | 2024-11-01 | 2024-08-06 | 2024-05-13 | 2024-03-14 | 2023-11-03 | 2023-08-04 | 2023-04-28 | 2023-03-16 |
| Reported EPS | -0.16 | -0.21 | -0.19 | -0.16 | 0.06 | -0.23 | -0.18 | -0.05 | -0.18 | -0.2 | -0.21 | -0.23 |
| Estimated EPS | -0.1898 | -0.1742 | -0.207 | -0.1903 | -0.23 | 0.27 | -0.14 | -0.11 | 0.03 | -0.19 | -0.23 | -0.25 |
| Surprise | 0.0298 | -0.0358 | 0.017 | 0.0303 | 0.29 | -0.5 | -0.04 | 0.06 | -0.21 | -0.01 | 0.02 | 0.02 |
| Surprise Percentage | 15.7007% | -20.5511% | 8.2126% | 15.9222% | 126.087% | -185.1852% | -28.5714% | 54.5455% | -700% | -5.2632% | 8.6957% | 8% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.1865 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACIU
2025-11-02 11:53:48
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on AC Immune SA with a $12.00 price target, citing the company's innovative vaccine platform for neurodegenerative diseases. Key drivers for the rating include promising vaccine candidates for Alzheimer's, tauopathies, and Parkinson's, as well as a significant breakthrough in TDP-43 PET tracer development, expanding AC Immune's diagnostic and therapeutic potential. This strategic expansion beyond vaccines enhances the company's value proposition.
2025-10-12 19:50:18
AC Immune SA reached a new 52-week high of USD 3.99 on October 3, 2025, marking a significant milestone for the microcap biotechnology company with a market capitalization of USD 231 million. Despite this recent high, the company's one-year performance shows an 11.53% decline, contrasting with the S&P 500's gain, and it faces financial challenges including negative return on equity and debt-to-equity ratio. The stock's previous 52-week low was USD 1.43, indicating a substantial upward movement from that point.
2025-10-08 19:21:00
AC Immune (ACIU) shares rose 24.2% after the publication of positive Phase 1b/2a trial results for its active immunotherapy ACI-35.030 in Alzheimer's disease, showing a robust immune response and no significant safety issues. This development reinforces investor confidence despite ongoing profitability and operational risks, with future clinical results becoming critical for shareholder sentiment. The Simply Wall St community fair value estimates for AC Immune widely range from CHF 7.93 to CHF 150, reflecting varied perspectives on the company's trajectory.
2025-10-08 00:00:00
AC Immune (ACIU) shares rose 24.2% following the publication of positive Phase 1b/2a trial results for its active immunotherapy ACI-35.030 in Alzheimer's disease. The data showed a rapid, robust, and durable immune response against Tau proteins with good safety and tolerability. While this is a positive development for AC Immune's investment narrative, the company still faces challenges including unprofitability and leadership changes.
2025-10-07 06:36:00
AC Immune SA (ACIU), a clinical-stage biopharmaceutical company, is set to reach multiple pipeline milestones in the coming months, which could significantly impact its stock price. The company has several investigational products across active immunotherapies, small-molecule drugs, and diagnostics, with key data readouts and potential licensing payments on the horizon. Investors will be watching for interim results from trials for Alzheimer's and Parkinson's disease treatments, as well as progress on early-stage diagnostics and drug candidates.
2025-09-04 07:50:00
AC Immune SA has announced a strategic pipeline focus, concentrating investments on key assets like active immunotherapy programs for Alzheimer's and Parkinson's diseases and high-value intracellular targeting candidates. This strategic shift includes a workforce reduction of approximately 30% to enhance operational efficiencies and extend the company's cash runway to Q3 2027. Despite these changes, the company maintains a strong cash position of CHF 127.1 million and expects to meet its clinical milestones for ongoing programs.
